ClinicalTrials.gg
WithdrawnNCT02678234Updated Mar 12, 2018

An Efficacy and Safety Study of Theraflu Day Powder as Oral Solution for Cold and Flu

A Phase 3 interventional study of Paracetamol, phenylephrine HCl, and vitamin C in Infections, Respiratory Tract, sponsored by GlaxoSmithKline. Withdrawn. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2018-03-12.

Sponsored by GlaxoSmithKline · Phase 3, Interventional, and Treatment

Why this study was withdrawn
The clinical phase of the study (from FSFV to LSLV) was never initiated due to the sponsor's decision.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
0
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 21 studies in Respiratory Tract Infections by GlaxoSmithKline — none open to participants now, none under way, none of them phase 3. Respiratory Tract Infections · GlaxoSmithKline.

Enrollment
18th of 19
0 · median 46
Started
2017
with 1 other
Phase 3
4 of 21
none open now
Registered
18th of 21
by date

Among the 21 studies in Respiratory Tract Infections by GlaxoSmithKline, this one is the 18th largest by enrollment of the 19 interventional ones that give a count, is one of 2 that started in 2017, is one of 4 in phase 3, and was the 18th registered.

Respiratory Tract Infections

753 studies on the registry are indexed under Respiratory Tract Infections; 114 are open to participants now.

Browse Respiratory Tract Infections studies →

Open to participants now

None of the 21 studies in Respiratory Tract Infections by GlaxoSmithKline is open now. The open studies under Respiratory Tract Infections, anywhere →

Who these studies take

Of the 74 Respiratory Tract Infections studies recruiting now, 35 (47%) set no upper age limit and 31 (42%) stop at 75 or younger; 34 take children under 18; 25 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 21 studies in Respiratory Tract Infections by GlaxoSmithKline as a file.
02

Study summary

The purpose of the study is to assess the short term efficacy of the Theraflu Aktiv powder for oral solution in the Russian population as compared to an untreated group to support the indication of "Short term relief of the symptoms of colds, chills and influenza, including mild to moderate pain, fever and nasal congestion".

03

Conditions studied

  • Infections, Respiratory Tract
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Participants must understand and provide written before any assessment is performed, understand the study procedures, and be willing and able to complete the required assessments
  • Males and females ≥ 18 years
  • Clinical diagnosis of a URTI as diagnosed by the investigator which would be classified as ICD-10 code J00 (acute nasopharyngitis common cold)
  • Mild to moderate sore throat, i.e. rated as 1 or 2 on a 4-point ordinal scale (0=not present, 1= mild, 2=moderate, 3=severe), or headache (1, 2 or 3) or fever (less than 39°C ) or/and Nasal congestion (blocked nose): may be accompanied by rhinorrhea (runny nose) and/or sneezing
  • Baseline Jackson TSS > 8
  • Common cold symptoms for less than 48 hours

Exclusion criteria

Exclusion Criteria:

  • Use of other drugs within 30 days or 5 half-lives of enrollment, whichever is longer. Investigational drug refers to any drug being evaluated in clinical trials
  • History of or known to any of the study drugs, or to drugs of similar chemical classes
  • Sacharoze/maltose deficiency, fructose intolerance, glucosegalactose malabsorbtion
  • Pregnant or nursing (lactating) women, where pregnancy is defined as the state of a female after conception and until the termination of gestation, confirmed by a positive hCG laboratory test (> 5 mIU/mL) or urine dipstick at baseline
  • Any history of drug hypersensitivity, asthma, urticaria, or other significant allergic diathesis. participants with uncomplicated seasonal allergic rhinitis can be accepted if expected allergy season is clearly one month outside enrollment/ treatment period
  • Any history of brain diseases, liver diseases or epilepsy
  • Any evidence of uncontrolled cardiovascular (including hypertension), pulmonary, renal, hepatic, gastrointestinal, hematological, endocrinological, metabolic, neurological or psychiatric diseases at screening
  • Subject has closed angle glaucoma, urinary retention, prostatic hyperplasia, pyloroduodenal obstruction, pheochromocytoma, diabetes mellitus
  • A positive alcohol breath test or positive urine drug screen or a medical history data indicative of alcoholism, drug addiction, or drug abuse within the preceding 2 years
  • Subject is current smoker of ≥10 cigarettes per day (or reports equivalent smoking habits using other tobacco products) and is unwilling to refrain from smoking while at the study site
  • Subject is current smoker of ≥10 cigarettes per day (or reports equivalent smoking habits using other tobacco products) and is unwilling to refrain from smoking while at the study site
  • Subject is taking or has taken within the last two weeks of dosing monoamine oxidase inhibitors, antidepressants, atropine, beta-blocking or sympathomimetic drugs desferrioxamine, hepatotoxic drugs, drugs inducing liver microsomal enzyme, (such as phenytoin, carbamazepine, isoniazid and rifampicin), neuroleptic drugs, chlorzoxazone, CNS depressant drugs including barbiturates, hypnotics, opioid analgesics, anxiolytic sedatives, antipsychotics or is anticipated to require any of these medications at any time throughout the study
  • Subject has used: Systemic or topical (with the exception of HRT and steroids for females), within 3 weeks prior to dosing or Slow-release steroids (with the exception of HRT and contraceptive steroids for females) within 90 days prior to dosing
  • Subject has used any of the following medications within 6 hours before first study drug administration, or is anticipated to use any of these medications at any time throughout the study: Any inhaler, medicated confectionary, throat lozenges, throat pastilles, sprays, any products with demulcent properties such as chewing gums and boiled sweets or mints, Any medication for sore throat containing a local anesthetic, Cold products and oral nasal decongestant products, Paracetamol or any NSAID
  • Subject has used substances of abuse, herbal medicines, antihistamines and homeopathic medicine within 72 hours of dosing or is anticipated to require any of these drugs at any time throughout the study
  • Subject was previously enrolled into the current study
  • Persons directly or indirectly involved in the execution of this protocol, including first-degree relative of a study investigator, employees of the clinical study site, employees of the CRO and persons related to them
  • "Vulnerable" individual (as defined by the IRB e.g. incarcerated person)
Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
0 participants (actual)

Study arms

  • Experimental
    Theraflu Aktiv powder for oral solution

    Participants in this arm will receive a single dose (1 sachet) of Theraflu Aktiv powder for oral solution

    Drug: Paracetamol, phenylephrine HCl, and vitamin C

  • No intervention
    No Treatment

    Participants in this arm will not receive any medication

Interventions

  • DrugParacetamol, phenylephrine HCl, and vitamin C

    One sachet is provided for each participant randomized to the Theraflu Aktiv powder for oral solution

    Also known as: Theraflu Aktiv powder for oral solution

06

What researchers measure

Primary outcomes

  1. Efficacy assessment

    The severity of common cold symptoms will be self-assessed using the Jackson 8 items scale (questionnaire) by the participants on the site. This questionnaire measures the severity of 5 local symptoms (nasal congestion, rhinorrhea, sneezing, cough, and sore throat) and 3 systemic symptoms (chilliness, headache, malaise) each on a 4-point ordinal scale (0=not present, 1= mild, 2=moderate, 3= severe).

    Time frame: Baseline and 3 hours post dosing

07

Study locations

No study locations are listed for this record.

08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Start is estimated for Feb 2017; primary completion for Apr 2017, 2 months later.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 4, 2016
First posted
Feb 9, 2016
StartEst.
Feb 1, 2017
Primary completionEst.
Apr 1, 2017
CompletionEst.
Apr 1, 2017
Last update
Mar 12, 2018
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 12, 2018, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT02678234
Lead sponsor
GlaxoSmithKline
Responsible party
Sponsor
First posted
Feb 9, 2016
Start date
Feb 1, 2017 (estimated)
Primary completion
Apr 1, 2017 (estimated)
Completion
Apr 1, 2017 (estimated)
Last update
Mar 12, 2018

Study contacts

GSK Clinical Trials
study director · GlaxoSmithKline

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is withdrawn, as verified in Mar 2018. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion